Tower Research Capital (TRC)’s Lantern Pharma LTRN Stock Holding History
Bought
Maintained
Sold
Other funds holding LTRN
BCM
VCM
CM
WIM
VC
VFT
Tower Research Capital (TRC)'s LTRN Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Lantern Pharma (LTRN) stake by 324% in Q1 2026, buying an estimated $7.63K and bringing the position to 3,569 shares worth $4.89K. The position accounts for ﹤0.01% of the portfolio, ranked #4160.
Tower Research Capital (TRC) first reported a position in LTRN in Q2 2020 and has held it in 24 quarters since. The position peaked at $29.5K in Q1 2024. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.
- Tower Research Capital (TRC) held 3,569 shares of Lantern Pharma worth $4.89K as of Q1 2026.
- Tower Research Capital (TRC) bought 2,728 Lantern Pharma shares in Q1 2026, an estimated $7.63K.
- Lantern Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4160 holding.
- Tower Research Capital (TRC) first reported a position in Lantern Pharma in Q2 2020 and has held it in 24 quarters since.
- Tower Research Capital (TRC)'s Lantern Pharma position peaked at $29.5K in Q1 2024.
- 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.